Every 10-Q that Phio Pharmaceuticals Corp (PHIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PHIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHIO filings page.
Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing cancer immunotherapies based on its proprietary INTASYL self-delivering siRNA platform. Lead program PH-762 targets PD-1 to enhance T-cell killing of tumors, with a second program, PH-894, targeting BRD4; the PH-894 IND has been deferred while PH-762 is prioritized.
In a completed U.S. Phase 1b trial of intratumoral PH-762 in cutaneous squamous cell carcinoma and other skin cancers, 13 of 20 cSCC patients had pathologic responses, supporting a 65% overall response rate, including 9 complete responses, with PH-762 reported as well tolerated and without dose-limiting toxicities. A pivotal GLP toxicology study and new cGMP drug substance and product manufacturing are underway, and an FDA meeting request is targeted for the third quarter of 2026 to discuss next-step development.
Phio reported no product revenue and an increased focus on development spending. For the quarter ended June 30, 2026, research and development expenses were $3,082 (thousands) and net loss was $4,138 (thousands); for the six-month period, net loss was $8,141 (thousands). Cash and cash equivalents were $12,996 (thousands) at June 30, 2026, versus $21,031 (thousands) at year-end 2025. The company believes this cash, together with prior 2025 financings, will fund planned obligations for at least 12 months, and it has established an at-the-market program permitting sales of up to $6,360,000 of common stock, with no shares sold to date.
Phio Pharmaceuticals Corp. reported a net loss of $4.0M for the quarter ended March 31, 2026, wider than the prior-year loss of $1.8M, as it ramped spending on its lead cancer drug PH-762.
Research and development expenses rose to $2.8M from $0.9M, driven mainly by nonclinical, clinical and manufacturing work on PH-762. General and administrative costs increased to $1.4M from $1.0M, reflecting higher stock-based compensation, bonuses and professional fees.
Cash and cash equivalents were $17.0M at quarter-end, down from $21.0M at December 31, 2025. Management believes this, along with proceeds from 2025 financings, will fund operations for at least 12 months. The company also put in place a new at-the-market equity program allowing sales of up to $6.36M of common stock to support PH-762’s expected Phase 2b/3 trial and general working capital.
Phio Pharmaceuticals (PHIO) reported Q3 2025 results showing a net loss of $2.392 million on operating expenses of $2.505 million. Cash and cash equivalents were $10.705 million as of September 30, 2025, up from $5.382 million at year-end 2024, reflecting warrant exercises and registered direct offerings.
Subsequent to quarter-end, Phio entered inducement agreements that generated approximately $13.4 million in gross proceeds, with anticipated fees of $1.3 million, and issued new Series A warrants. The company states it believes it has sufficient liquidity for at least 12 months with these proceeds. Shares outstanding were 5,784,770 at September 30, 2025, and 10,764,428 as of November 11, 2025.
R&D expense was $1.181 million in Q3, driven by PH-762 clinical and CMC activity; G&A was $1.324 million. Year-to-date net loss was $6.327 million. In its ongoing Phase 1b trial of intratumoral PH-762, the fifth cohort showed 100% tumor clearance in one patient, >90% in a second, and >50% in a third at Day 36; no dose-limiting toxicities have been observed to date.
Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.
The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.